🔗 Share this article

As America continues making sweeping changes to its vaccination schedules, a particular individual has surfaced in a surprising turn: Dr. Tracy Beth Høeg, a Danish American physician and public health researcher who initially gained attention by expressing skepticism about Covid shots during the pandemic and has concentrated on alleged deaths after COVID-19 immunization in her recent position at the FDA.

Planned Overhauls to Pediatric Immunization Program

Agency leaders were set to unveil major changes to the pediatric vaccine schedule recently, bringing the US with Denmark’s immunization schedule, according to reports – a substantial departure that would place the US out of alignment with a large portion of the international standard with no evidence for benefit. This reveal has been delayed until the next year.

Rather than Vinay Prasad, Høeg is scheduled to address the audience at the meeting. She was recently named acting director of the FDA’s drug evaluation center, the fifth individual to lead the division this year.

A Shift at the Regulatory Body

The acting appointment may indicate a strengthened alliance between the pharmaceutical and vaccine branches as Høeg and Dr. Prasad solidify control at the regulatory agency – and it suggests a greater focus upon dismantling previously authorized immunizations at the FDA.

Dr. Høeg has repeatedly called for ending some childhood immunization guidelines in the US so as to align more like the Danish model, a country with comprehensive healthcare and a citizenry about the size of the state of Wisconsin.

In her initial public appearances, she has kept her attention on immunizations – usually the domain of Prasad, chief of the FDA’s vaccine center – as opposed to pharmaceutical oversight.

Questions Over Expertise

Høeg has no obvious experience in pharmaceutical research, approval processes or management, which has been standard for previous heads of the biologics center. She has been employed at the FDA as a senior adviser to the commissioner and CBER since earlier this year.

“It seems she lacks to have any of the qualifications” for overseeing the drug-regulation department, remarked a neurologist and psychiatrist. “She has not conducted a randomized controlled trial. She has no expertise in leading a sizeable institution. She has no expertise in industry regulation.”

Former commissioners of the center would “grasp legal statutes and the science of drug development”, commented a former acting FDA commissioner. “Clearly, she doesn’t have the kind of background that former directors who headed CBER have had.”

The drug center has an immense workload at the agency, the former commissioner stated.

“Everybody just focuses on the new drug program, but the off-patent medication office authorizes thousands of generic medications. There is also a biosimilars division, over-the-counter program and so forth, and all of those have to be looked after,” Woodcock explained. “The responsibility you neglect, that is the part that I always told people is going to bite you.”

Additionally, a substantial leadership element to the job, which oversees in excess of 5,000 staff members. “It is a enormous leadership role, if you do it right,” the former official concluded.

Official Statement and Controversial Programs

When asked about concerns about Høeg’s credentials and whether this selection represents increased cooperation among FDA leaders on vaccines, a spokesperson stated that the “inquiries are based on incorrect premises”.

“This background aligns with the functions of her role,” the representative stated, noting the months Høeg spent guiding the FDA commissioner on “drug safety and regulatory science, including predictive safety algorithms and vaccine surveillance”.

In her interim role, Dr. Høeg inherits the agency head's new priority voucher program, a disputed expedited therapy clearance system that allegedly troubled her former heads. “How are these medications being selected for this expedited pathway? Who makes the calls?” Dr. Howard asked. “There is a lot of secrecy occurring at the FDA right now.”

Broadly speaking, he stated, “the FDA looks to be trending towards laxer regulations of pharmaceuticals, with the exception of vaccines.”

Established History on Immunizations

Concerning immunizations, Høeg has a more established, if problematic, history, critics said. She released a analysis using unconfirmed volunteer-provided data to estimate the rate of myocarditis after COVID-19 immunization. She advised the state of Florida surgeon general Dr. Joseph Ladapo, who was said to have modified findings to imply COVID-19 vaccines are more dangerous than they are.

Among her “wish list” for the incoming government encompassed revising regulations for recently developed shots and halting “unnecessary” immunizations, she said post-election on a audio program. At the agency, Høeg has according to sources suggested excluding adolescent males from getting COVID-19 vaccinations.

“She’s an thorough dogmatist who starts off with her conclusions and works backwards to accommodate the science in a extremely misleading, fraudulent way,” Howard argued.

Gaining Influence and a “Campaign of Retribution”

Høeg joined fellow contrarians, {like|